We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. ANI Pharmaceuticals (ANIP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ANI Pharmaceuticals is a member of our Medical group, which includes 932 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ANI Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ANIP's full-year earnings has moved 6.2% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ANIP has returned about 8% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 7.1% on average. This means that ANI Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Aveanna Healthcare (AVAH - Free Report) . The stock has returned 19.5% year-to-date.
The consensus estimate for Aveanna Healthcare's current year EPS has increased 13.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 453 individual stocks and currently sits at #98 in the Zacks Industry Rank. On average, this group has gained an average of 18.6% so far this year, meaning that ANIP is slightly underperforming its industry in terms of year-to-date returns.
In contrast, Aveanna Healthcare falls under the Medical - Outpatient and Home Healthcare industry. Currently, this industry has 14 stocks and is ranked #106. Since the beginning of the year, the industry has moved +11.4%.
Investors interested in the Medical sector may want to keep a close eye on ANI Pharmaceuticals and Aveanna Healthcare as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. ANI Pharmaceuticals (ANIP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ANI Pharmaceuticals is a member of our Medical group, which includes 932 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ANI Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ANIP's full-year earnings has moved 6.2% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ANIP has returned about 8% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 7.1% on average. This means that ANI Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Aveanna Healthcare (AVAH - Free Report) . The stock has returned 19.5% year-to-date.
The consensus estimate for Aveanna Healthcare's current year EPS has increased 13.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ANI Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 453 individual stocks and currently sits at #98 in the Zacks Industry Rank. On average, this group has gained an average of 18.6% so far this year, meaning that ANIP is slightly underperforming its industry in terms of year-to-date returns.
In contrast, Aveanna Healthcare falls under the Medical - Outpatient and Home Healthcare industry. Currently, this industry has 14 stocks and is ranked #106. Since the beginning of the year, the industry has moved +11.4%.
Investors interested in the Medical sector may want to keep a close eye on ANI Pharmaceuticals and Aveanna Healthcare as they attempt to continue their solid performance.